Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ideaya Biosciences (IDYA)
:IDYA
IDYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.96 - $47.72
Previous CloseN/A
Volume96.34K
Average Volume (3M)889.28K
Market Cap
$1.90B
Enterprise Value$1.83B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.25
Next Earnings
May 13, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.30
Shares Outstanding87,537,390
10 Day Avg. Volume973,353
30 Day Avg. Volume889,282
Standard Deviation0.21
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)455.18
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit94.40
Enterprise Value/Ebitda-8.21
Forecast
1Y Price Target
$56.80Price Target Upside161.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
IDEAYA Biosciences News
PremiumCompany Announcements
IDEAYA Biosciences Reports 2024 Financials and Business Update
PremiumCompany Announcements
IDEAYA Biosciences Appoints New Chief Financial Officer
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's cash runway guidance extends at least into 2028, highlighting financial stability and the ability to continue operations without immediate need for additional funding.
Licensing AgreementIDYA announced a licensing deal with Jiangsu Hengrui, giving IDYA exclusive rights to a promising early-stage asset, enhancing its growing pipeline.
Partnership ExpansionIDYA announced an expansion of their collaboration with Gilead for MAT2A inhibitor IDE397 and Trodelvy to include MTAP deleted NSCLC along with MTAP deleted bladder cancer.
Bears Say
Regulatory ChallengesThe company's management noted that the timing for a conference readout on mUM data will be challenging.
Strategic RealignmentIDYA and AMGN agreed to wind down the combination of IDE397 plus AMG 193 and will not pursue dose expansion due to lack of sufficient enrollment and alignment on dose selection.
Strategic ShiftThe winding down of the collaboration with Amgen was expected, but reflects a shift in strategic focus for the company.
---
Ownership Overview
0.89% Insiders
34.30% Mutual Funds
28.95% Other Institutional Investors
22.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IDYA FAQ
What was Ideaya Biosciences’s price range in the past 12 months?
Ideaya Biosciences lowest stock price was $19.96 and its highest was $47.72 in the past 12 months.
What is Ideaya Biosciences’s market cap?
Ideaya Biosciences’s market cap is $1.90B.
When is Ideaya Biosciences’s upcoming earnings report date?
Ideaya Biosciences’s upcoming earnings report date is May 13, 2025 which is in 81 days.
How were Ideaya Biosciences’s earnings last quarter?
Ideaya Biosciences released its earnings results on Feb 13, 2025. The company reported -$1.49 earnings per share for the quarter, missing the consensus estimate of -$0.629 by -$0.861.
Is Ideaya Biosciences overvalued?
According to Wall Street analysts Ideaya Biosciences’s price is currently Undervalued.
Does Ideaya Biosciences pay dividends?
Ideaya Biosciences does not currently pay dividends.
What is Ideaya Biosciences’s EPS estimate?
Ideaya Biosciences’s EPS estimate is -0.67.
How many shares outstanding does Ideaya Biosciences have?
Ideaya Biosciences has 87,537,390 shares outstanding.
What happened to Ideaya Biosciences’s price movement after its last earnings report?
Ideaya Biosciences reported an EPS of -$1.49 in its last earnings report, missing expectations of -$0.629. Following the earnings report the stock price went down -5.421%.
Which hedge fund is a major shareholder of Ideaya Biosciences?
Currently, no hedge funds are holding shares in IDYA
---
IDEAYA Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.80 (161.39% Upside)
$56.80 (161.39% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 27.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.62%
12-Months-Change
Fundamentals
Return on Equity
-32.67%
Trailing 12-Months
Asset Growth
73.12%
Trailing 12-Months
Company Description
Ideaya Biosciences
IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
---
IDYA Stock 12 Month Forecast
Average Price Target
$56.80
▲(161.39% Upside)
Technical Analysis
Best Analysts Covering IDYA
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+39.41%
reiterated a buy rating 4 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +39.41% per trade.
---